CTLA4 binders
US10501542B2 · kind B2 · utility
14Cited by
6References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 17, 2016 |
| Grant date | Dec 10, 2019 |
| Priority date | — |
| Expiry date | Aug 14, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.